saline infusion, ketoprofen, paracetamol — Competitive Intelligence Brief

saline infusion, ketoprofen, paracetamol (saline infusion, ketoprofen, paracetamol) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NSAID. Area: Pain management.

phase 3 NSAID Pain management Small molecule

Target snapshot

saline infusion, ketoprofen, paracetamol (saline infusion, ketoprofen, paracetamol) — American University of Beirut Medical Center. Saline infusion is a solution of salt and water used to replenish fluids, ketoprofen is a nonsteroidal anti-inflammatory drug (NSAID) that reduces pain and inflammation, and paracetamol is an analgesic and antipyretic that reduces pain and fever.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
saline infusion, ketoprofen, paracetamol TARGET	saline infusion, ketoprofen, paracetamol	American University of Beirut Medical Center	phase 3	NSAID
Cytotec	Misoprostol	Pfizer	marketed	NSAID combined with prostaglandin analog	Cyclooxygenase (COX-1 and COX-2); Prostaglandin receptors	1988-01-01
Aleve	naproxen	Generic (originally Syntex)	marketed	NSAID	Aldo-keto reductase family 1 member C2, Aldo-keto reductase family 1 member C3, Prostaglandin G/H synthase 1	1976-01-01
Aspirin	acetylsalicylic acid	Bayer AG	marketed	NSAID, Antiplatelet agent	Gamma-glutamyltranspeptidase 1, Nicotinate phosphoribosyltransferase, Acid-sensing ion channel 3	1899-03-06
Pranoprofen eye drops	Pranoprofen eye drops	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase (COX-1, COX-2)
ketorolac + bupivacaine	ketorolac + bupivacaine	The Hospital for Sick Children	marketed	NSAID + local anesthetic combination	COX-1/COX-2 (ketorolac); voltage-gated sodium channels (bupivacaine)
ketorolac 0.5%	ketorolac 0.5%	Queen's University	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NSAID class)

1. Antibe Therapeutics Inc. · 3 drugs in this class
2. Iroko Pharmaceuticals, LLC · 3 drugs in this class
3. Organon and Co · 2 drugs in this class
4. Apsen Farmaceutica S.A. · 2 drugs in this class
5. Amneal Pharmaceuticals, LLC · 2 drugs in this class
6. Behar, Caren, M.D. · 2 drugs in this class
7. IDEA AG · 2 drugs in this class
8. Noven Pharmaceuticals, Inc. · 2 drugs in this class
9. HALEON · 2 drugs in this class
10. Pfizer · 2 drugs in this class